MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--VIVUS, Inc. (NASDAQ: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, announced that Abstract #1405, Reduction in Cardiovascular Risk Factors in Obese Adults Treated With Topiramate Plus Phentermine was presented on October 9, 2007 by its author, Dr. Kishore M. Gadde, at the 7th International Congress on Coronary Artery Disease (ICCAD) Conference in Venice, Italy. The abstract concludes that obese patients treated for 24 weeks with Qnexa, an investigational drug, had improvements in blood pressure, triglycerides, total cholesterol, and C-reactive protein.
